The current multidrug resistant Escherichia coli pandemic: exploring novel therapies against the predominant culprit E. coli ST131.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1069370

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Escherichia coli ST131 is a pandemic superbug. Like MRSA, E. coli ST131 infections are resistant to multiple antibiotics and can become life threatening. This study will show how adhesion can be the 'Achilles' heel' of this global pathogen and how blocking E. coli ST131 adhesion offers an alternative therapy for multidrug resistant human infections. As we are left with no effective antimicrobials to treat E. coli ST131 infections, this work will provide novel outcomes that are sorely needed.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $512,223.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Bacteriology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Escherichia coli | adhesins | fimbriae | infectious diseases | multidrug resistance | urinary tract infection (UTI) | virulence

Related Links